Cite
MLA Citation
Robert R. Redfield et al.. “Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐CD20 monoclonal antibody for the desensitization of candidates for renal transplant.” American journal of transplantation, vol. 19, no. 11, 2019, pp. 3035–3045. http://access.bl.uk/ark:/81055/vdc_100093293175.0x000015